New York Life Investment Management LLC acquired a new stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 20,495 shares of the company’s stock, valued at approximately $2,244,000. New York Life Investment Management LLC owned approximately 0.22% of VanEck Pharmaceutical ETF as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in PPH. Royal Bank of Canada lifted its position in VanEck Pharmaceutical ETF by 846.9% in the 1st quarter. Royal Bank of Canada now owns 361,001 shares of the company’s stock worth $37,501,000 after buying an additional 322,878 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of VanEck Pharmaceutical ETF by 139.3% during the 1st quarter. Bank of America Corp DE now owns 143,609 shares of the company’s stock valued at $14,918,000 after buying an additional 83,598 shares during the period. Fluent Financial LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the 2nd quarter valued at $4,264,000. Avior Wealth Management LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the 3rd quarter valued at $1,685,000. Finally, Commonwealth Equity Services LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the 3rd quarter valued at $1,171,000.
VanEck Pharmaceutical ETF Stock Performance
Shares of NASDAQ PPH traded up $1.35 during mid-day trading on Friday, reaching $122.65. The company had a trading volume of 193,783 shares, compared to its average volume of 320,706. VanEck Pharmaceutical ETF has a twelve month low of $97.52 and a twelve month high of $123.53. The stock has a market capitalization of $1.11 billion, a PE ratio of 29.81 and a beta of 0.43. The stock’s 50 day moving average is $113.65 and its 200-day moving average is $108.68.
VanEck Pharmaceutical ETF Cuts Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, October 6th. Investors of record on Thursday, October 1st were given a dividend of $0.36 per share. The ex-dividend date of this dividend was Thursday, October 1st. This is a negative change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248. This represents a $1.44 dividend on an annualized basis and a yield of 1.2%.
VanEck Pharmaceutical ETF Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Further Reading
- Five stocks we like better than VanEck Pharmaceutical ETF
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
